CARSON CITY, NV, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CECORS, INC. (OTC PINK: CEOS) ("CeCors" or the "Company"), through its wholly owned subsidiary PsyKey Inc., an innovative wellness company, is pleased to announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board.
Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties.
"Dr. McCarthy is a scientist who truly understands the important link between the chemical compounds in food and optimum health," said John Gustin, PsyKey head of global business development. "With his extensive knowledge of the biotechnical patent landscape, we are confident Dr. McCarthy will make significant contributions to our ongoing product development efforts."
"I am very excited to join PsyKey," said McCarthy. "There is a great deal of synergy between the interests of the research team at PsyKey and my long-term biomedical studies. For many years we've understood the neurological benefits of certain medicinal and psychedelic mushrooms, but we're just now unlocking the real potential of these remarkable fungi. I am confident my experience enhancing the potency and bio-availability of micro-nutrients will help further distinguish PsyKey, as an industry-leading innovative wellness company."
Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement.
With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
About PsyKey, Inc.
PsyKey, Inc. is an innovative wellness company that specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to medicinal PsyKey, Inc. believes in the magic of mushrooms. As part of its optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals. Management is continuously engaged in the development of tools that will aid in removing barriers and providing inclusivity.
For further information:
(OTC Pink: CEOS)
E-mail: info@psykeyworld.com
Follow us on Twitter:
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements.
CARSON CITY, NV, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CECORS, INC. (OTC PINK: CEOS) ("CeCors" or the "Company"), through its wholly owned subsidiary PsyKey Inc., an innovative wellness company, is pleased to announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board.
内华达州卡森市，2022年11月16日(环球通讯社)CECORS，Inc.(场外粉色：首席执行官)(“CeCors”或“公司”)，通过其全资拥有的子公司--一家创新的保健公司，宣布任命迈克尔·J·麦卡锡博士为其科学和医疗顾问委员会的成员。
Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties.
麦卡锡博士拥有35年以上担任生物制药行业顾问和制定高影响力药物和保健食品的经验。作为一名生物化学家和出版广泛的作家，麦卡锡博士在保护生物医学专利和知识产权方面为GeorKey提供了丰富的专业知识。
"Dr. McCarthy is a scientist who truly understands the important link between the chemical compounds in food and optimum health," said John Gustin, PsyKey head of global business development. "With his extensive knowledge of the biotechnical patent landscape, we are confident Dr. McCarthy will make significant contributions to our ongoing product development efforts."
“麦卡锡博士是一位科学家，他真正了解食品中的化合物与最佳健康之间的重要联系，”心理钥匙公司全球商业发展负责人约翰·古斯汀说。凭借他在生物技术专利领域的广博知识，我们相信麦卡锡博士将为我们正在进行的产品开发努力做出重大贡献。“
"I am very excited to join PsyKey," said McCarthy. "There is a great deal of synergy between the interests of the research team at PsyKey and my long-term biomedical studies. For many years we've understood the neurological benefits of certain medicinal and psychedelic mushrooms, but we're just now unlocking the real potential of these remarkable fungi. I am confident my experience enhancing the potency and bio-availability of micro-nutrients will help further distinguish PsyKey, as an industry-leading innovative wellness company."
麦卡锡说：“我很高兴能加入《心理钥匙》。他说：“我们的研究团队的兴趣和我的长期生物医学研究之间有很大的协同作用。多年来，我们已经了解了某些药用和迷幻蘑菇的神经益处，但我们现在才释放出这些非凡真菌的真正潜力。我相信，我提高微量营养素的效力和生物可利用性的经验将有助于进一步区分作为一家行业领先的创新健康公司。”
Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement.
在加入GeorKey之前，麦卡锡博士在斯克里普斯研究公司工作了8年，作为他们的生物技术专利代理人，斯克里普斯研究公司将其对创新的影响评为世界上最有影响力的机构，同时从事许多具有重大市场影响力的突破性技术。在他对生物医学领域的众多贡献中，麦卡锡博士开发了“制剂/增强剂”技术，以提高焦虑、癌症和睡眠改善疗法中使用的生化因子的效力。
With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
麦卡锡博士拥有本尼迪克廷学院的生物学和物理学学位，曾就读于约翰霍普金斯大学医学院，并在那里参加了生物化学、细胞和分子生物学项目。麦卡锡后来在范德比尔特大学生物化学系获得博士学位。他在范德比尔特大学内分泌学的博士后研究包括开发病毒和转基因系统，从而逆转实验室动物的动脉粥样硬化。
PsyKey, Inc. is an innovative wellness company that specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to medicinal PsyKey, Inc. believes in the magic of mushrooms. As part of its optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals. Management is continuously engaged in the development of tools that will aid in removing barriers and providing inclusivity.
辛基公司是一家创新的保健公司，专门从事以真菌学为基础的致病、致适应和促性成分和配方的开发和商业化。从功能到药用，心理钥匙公司相信蘑菇的魔力。作为其最佳健康战略的一部分，CogKey了解获得支持服务和医疗保健专业人员的重要性。管理层不断致力于开发有助于消除障碍和提供包容性的工具。
E-mail: info@psykeyworld.com
Follow us on Twitter:
电子邮件：info.ping.com.cn
在推特上关注我们：
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements.
前瞻性陈述：
安全港声明-除历史信息外，本新闻稿可能包含符合1933年《证券法》和经1995年《私人证券诉讼改革法》修订的1934年《证券交易法》所指的前瞻性陈述。本新闻稿中包含的前瞻性陈述包括公司及其管理团队成员对公司未来业务运营的意图、信念或期望，以及这些陈述所基于的假设。提醒潜在投资者，任何此类前瞻性陈述都不是对未来业绩的保证，涉及风险和不确定因素，实际结果可能与此类前瞻性陈述中预期的大不相同。可能导致这些差异的因素包括但不限于：未能完成谈判中的预期销售、收入增长乏力、客户中断、未能实现业绩、效率和盈利能力的改善，以及诉讼或诉讼成本增加、公司业务部门的运营或业绩或其普通股的市场价格方面的不利发展。其他可能导致实际结果与本新闻稿中预期的大不相同的因素也可以在公司网站上找到。公司不承担任何更新任何前瞻性陈述的责任。
